These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Vlassara H; Bucala R; Striker L Lab Invest; 1994 Feb; 70(2):138-51. PubMed ID: 8139257 [No Abstract] [Full Text] [Related]
3. Diabetes and advanced glycoxidation end products. Huebschmann AG; Regensteiner JG; Vlassara H; Reusch JE Diabetes Care; 2006 Jun; 29(6):1420-32. PubMed ID: 16732039 [No Abstract] [Full Text] [Related]
4. Inhibition of advanced glycated end-products. Gandhi JS; Patel V Postgrad Med J; 1999 Jul; 75(885):446-7. PubMed ID: 10474742 [No Abstract] [Full Text] [Related]
5. [Long-term complications in diabetes mellitus: role of irreversible glycosylation products]. Treskes M; Wolffenbuttel BH Ned Tijdschr Geneeskd; 1996 Jun; 140(25):1299-303. PubMed ID: 8710007 [No Abstract] [Full Text] [Related]
6. [Accumulation of AGE (advanced glycosylation end-products) in the aging process, in diabetes mellitus and in chronic renal failure]. Wisotzky J; Sommer M; Schubert K; Stein G Med Klin (Munich); 1996 Jul; 91(7):454-7. PubMed ID: 8756114 [No Abstract] [Full Text] [Related]
7. Influence of advanced glycation end-products in the development of atherosclerosis. Odetti P Ital Heart J; 2001 Sep; 2 Suppl 3():34S-36S. PubMed ID: 11593929 [No Abstract] [Full Text] [Related]
9. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Kalousová M; Zima T; Tesar V; Dusilová-Sulková S; Skrha J Mutat Res; 2005 Nov; 579(1-2):37-46. PubMed ID: 16084533 [TBL] [Abstract][Full Text] [Related]
10. [Role of enzymatic cross-links and non-enzymatic cross-link, advanced glycation end products, as a determinant of bone quality in osteoporosis and diabetes]. Saito M Nihon Rinsho; 2007 Nov; 65 Suppl 9():209-13. PubMed ID: 18161108 [No Abstract] [Full Text] [Related]
11. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Rojas A; Morales MA Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904 [TBL] [Abstract][Full Text] [Related]
12. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Friedman EA Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902 [TBL] [Abstract][Full Text] [Related]
13. [Advanced glycosylation end products or glycotoxins: under-evaluated components of diet?]. Wautier JL Rev Prat; 2001 Sep; 51(13):1397-9. PubMed ID: 11601066 [No Abstract] [Full Text] [Related]
14. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Machado AP; Pinto RS; Moysés ZP; Nakandakare ER; Quintão EC; Passarelli M Int J Biochem Cell Biol; 2006 Mar; 38(3):392-403. PubMed ID: 16288898 [TBL] [Abstract][Full Text] [Related]
15. The Maillard reaction and its consequences for a living body. Sztanke K; Pasternak K Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):159-62. PubMed ID: 15323185 [TBL] [Abstract][Full Text] [Related]
16. Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Yoon MS; Jankowski V; Montag S; Zidek W; Henning L; Schlüter H; Tepel M; Jankowski J Biochem Biophys Res Commun; 2004 Oct; 323(2):377-81. PubMed ID: 15369762 [TBL] [Abstract][Full Text] [Related]
17. Oxidative stress parameters in hemodialysis patients with or without diabetes. Atanasiu V; Stoian I; Căpuşă C; Mircescu G; Mărăcine M; Lupescu O; Vîrgolici B; Muscurel C; Manolescu B Rom J Intern Med; 2006; 44(4):433-42. PubMed ID: 18386620 [TBL] [Abstract][Full Text] [Related]